Role of RNF4 in the Ubiquitination of Rta of Epstein-Barr Virus*

Received for publication, August 24, 2012, and in revised form, March 15, 2013 Published, JBC Papers in Press, March 15, 2013, DOI 10.1074/jbc.M112.413393

Ya-Chun Yang†, Yushi Yoshikai‡, Shih-Wei Hsu*, Hisato Saitoh†, and Li-Kwan Chang‡,§

From the *Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, 106, Taiwan and the ‡Department of Biological Sciences, Graduate School of Science and Technology, Kumamoto University, 2-39-1 Kurokami, Kumamoto 860-8555, Japan

Background: Rta is a transcription factor encoded by Epstein-Barr virus (EBV) that activates the transcription of viral lytic genes and promotes lytic development.

Results: RNF4 enhances the ubiquitination of Rta, thus decreasing lytic replication and virions production.

Conclusion: RNF4 targets SUMO-2-conjugated Rta and promotes Rta ubiquitination.

Significance: RNF4 is a SUMO-targeted ubiquitin ligase of Rta that modulates the amount of Rta during EBV lytic progression.

Epstein-Barr virus (EBV) encodes a transcription factor, Rta, which is required to activate the transcription of EBV lytic genes. This study demonstrates that treating P3HR1 cells with a proteasome inhibitor, MG132, causes the accumulation of SUMO-Rta and promotes the expression of EA-D. GST pull-down and coimmunoprecipitation studies reveal that RNF4, a RING-domain-containing ubiquitin E3 ligase, interacts with Rta. RNF4 also targets SUMO-2-conjugated Rta and promotes its ubiquitination in vitro. Additionally, SUMO interaction motifs in RNF4 are important to the ubiquitination of Rta because the RNF4 mutant with a mutation at the motifs eliminates ubiquitination. The mutation of four lysine residues on Rta that abrogated SUMO-3 conjugation to Rta also decreases the enhancement of the ubiquitination of Rta by RNF4. This finding demonstrates that RNF4 is a SUMO-targeted ubiquitin E3 ligase of Rta. Finally, knockdown of RNF4 enhances the expression of Rta and EA-D, subsequently promoting EBV lytic replication and virions production. Results of this study significantly contribute to efforts to elucidate a SUMO-targeted ubiquitin E3 ligase that regulates Rta ubiquitination to influence the lytic development of EBV.

As a reversible posttranslational modification process, ubiquitination influences diverse biological functions (1, 2). Ubiquitin (Ub) is covalently attached to protein substrates by a cascade of enzymatic reactions mediated by activating enzymes (E1), conjugating enzymes (E2), and ligases (E3). As is commonly known, ubiquitination leads to degradation of a target protein by 26 S proteasome; the degradation is associated with a polyUb chain that is linked through Lys-48 of Ub (3, 4). After linking to a target protein, the process of polyubiquitination is reversed by deubiquitinases (5). Similar to ubiquitin, a small ubiquitin-like modifier (SUMO) is covalently attached to lysine residues of target proteins via an isopeptide bond by a mechanism resembling that of ubiquitination (6). Eukaryotes express three SUMO isoforms (SUMO-1, SUMO-2, and SUMO-3) of which SUMO-2 and SUMO-3, which have internal consensus modification sites, allow the formation of polySUMO chains on target proteins (7, 8). SUMO-1, rather forming a SUMO chain like SUMO-2 and SUMO-3, modifies a protein by linking a single molecule to lysine residues or serves as a terminator of a SUMO chain (8, 9). Sumoylation often affects protein functions, including transcription, subcellular localization, DNA repair, protein-protein interaction, and protein stability (10–13). In addition to covalent SUMO modification, proteins also interact noncovalently with SUMO via a region called SUMO-interacting motifs (SIMs) (14). SIM is critical to protein sumoylation and mediating interaction with other SUMO-modified proteins (15–19).

Schimmel et al. (20) found that treating cells with a 26 S proteasome inhibitor, MG132, accumulates the proteins conjugated by SUMO-2 but not those conjugated by SUMO-1, suggesting that ubiquitination depends on sumoylation by SUMO-2 (11, 21, 22), and polySUMO chains formed by SUMO-2 serves as an ubiquitination signal. The finding leads to the discovery of a family of SUMO-targeted ubiquitin ligases (STUbLs) that selectively ubiquitinate sumoylated proteins via SIMs (16, 21, 23–25). These STUbLs are important to cellular functions because the dysfunction of the gene in yeast causes the accumulation of SUMO-conjugated proteins and genome instability (23). Meanwhile, Ring-finger protein 4 (RFN4) is a human protein of the STUbL family containing SIM and the RING domain (16, 26) that promotes ubiquitination of SUMO-2-conjugated PML (15, 27). RFN4 also promotes the ubiquitination of kinetochore protein CENP-I, hypoxia-inducible factor 2α (HIF2α), and Sp1 by the same mechanism (28–30). A structural study indicated that dimeric RFN4 RING domains facilitate ubiquitin transfer by binding to the E2-ubiquitin thioester, thus promoting efficient transfer of ubiquitin to its substrates (31). Furthermore, RFN4 interacts with DNA glycosylase and apurinic/apyrimidinic site endonuclease to active
demethylation (32) and is important to DNA damage response and promotes DNA double-strand break repair (33–35). Additionally, Tax oncoprotein from HTLV-I is targeted by RNF4 to relocalize from the nucleus to the cytoplasm (36).

Although normally maintained under latent conditions in B lymphocytes, Epstein-Barr virus (EBV) must enter a lytic cycle to produce infectious virions. During reactivation from latency, EBV expresses two transcription factors, Rta and Zta, that are encoded by BRLF1 and BZLF1, respectively, to activate the EBV lytic cycle. To induce the EBV lytic cycle, P3HR1 cells were treated with 3 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA) and 3 mM sodium butyrate for 24–48 h and 293T cells, which were cultured in RPMI 1640 medium. The media were supplemented in 10% fetal calf serum. To induce the EBV lytic cycle, 293T cells were cultured in Dulbecco’s modified Eagle’s medium. The media were supplemented with 10% fetal calf serum. To induce the EBV lytic cycle, P3HR1 cells were treated with 3 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA) and 3 mM sodium butyrate for 24–48 h, and 293T cells, which were cultured in RPMI 1640 medium. The media were supplemented in 10% fetal calf serum. To induce the EBV lytic cycle, P3HR1 cells were treated with 3 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA) and 3 mM sodium butyrate for 24–48 h, and 293T cells, which were cultured in Dulbecco’s modified Eagle’s medium. The media were supplemented with 10% fetal calf serum.

Plasmids—Plasmid pGEX-4T1, which expresses GST, was purchased from Amersham Biosciences. Plasmids pHis-UbcH5a, pGEX-RNF4, and pEGFP-RNF4 encode His-UbcH5a, RNF4, and GFP-RNF4, respectively.4 Plasmids pBMLF1, pCMV-R, pFLAG-Rta, and pET-Rta were described elsewhere (41, 44, 46). Plasmid pFLAG-Ub, which expressed FLAG-tagged ubiquitin, was constructed by inserting a PCR-amplified DNA fragment that encoded ubiquitin into the EcoRI-HindIII sites in pCMV-Tag2B (Stratagene). Plasmid pT-E1E2S2 contains SUMO E1-, SUMO E2-, and SUMO-2-coding sequences on polySUMO-2-Rta according to a method described earlier (53). His-Rta and His-UbcH5a were purified from the E. coli BL21(DE3)(pET-Rta) and E. coli BL21(DE3)(pET-Ubc5a) lysates, respectively, using Ni²⁺-NTA-Sepharose beads using the method described elsewhere (44).

GST Pulldown Assay—GST, GST-RNF4, and His-Rta were purified from E. coli BL21(DE3)(pGEX-4T1), E. coli BL21(DE3)(pGEX-RNF4), and E. coli BL21(DE3)(pET-Rta), respectively. GST pulldown was performed according to a method described elsewhere (44).

Immunoprecipitation Assay—P3HR1 cells, which were treated with TPA and sodium butyrate for 24 h, and 293T cells, which had been transfected by plasmids for 24 h, were treated with 5 μM MG132 for 12 h. Lysates were prepared using HEPES buffer (12 mM HEPES and 0.5% Nonidet P-40) and centrifuged at 13,800 × g for 5 min. Anti-Rta antibody (Argene) or anti-RNF4 antibody (Sigma) was mixed with the supernatant at 4 °C for 1 h. Protein-A- or protein-G-agarose beads (30 μl) (Oncogene, Boston, MA) were added to the lysate, and the mixture was incubated under shaking for 1 h at 4 °C. The beads were collected by centrifugation and washed three times with HEPES buffer. Proteins binding to the beads were eluted by adding 20 μl of 2 × electrophoresis sample buffer and analyzed by immunoblotting using anti-Rta and anti-RNF4 antibodies. To detect sumoylated or ubiquitinated proteins, cells were harvested and washed with PBS containing 10 mM N-ethylmaleimide. Cells were solubilized and sonicated in 100 μl of SUMO protective buffer (44, 57) containing 1% SDS and then incubated at 95 °C for 10 min. The supernatant was then diluted with 900 μl of phosphate-buffered saline (PBS) containing 0.5% Nonidet P-40 and incubated with anti-FLAG antibody that was conjugated to M2-agarose beads (Sigma), anti-HA antibody (Roche Applied Science), or anti-Rta antibody to perform immunoprecipitation. Cells were incubated for 24 h after transfection and then treated with MG132 for an additional 12 h to detect sumoylated or ubiquitinated proteins.

Immunofluorescence Analysis—P3HR1 cells were transfected with pEGFP-C1 or pEGFP-RNF4 and then treated with TPA and sodium butyrate to activate the EBV lytic cycle. After culturing for 24 h, cells were treated with 5 μM MG132 for an additional 12 h.

Chung Chang. Plasmid pHA-Rta(4K-R) that contains lysine-to-alanine substitutions at amino acid positions 426, 446, 517, and 530 in Rta was constructed by a PCR mutagenesis method (55). Plasmids pHA-Rta and pHA-3K-R were described earlier (44). Plasmid pEGFP-PML was generated by inserting a PML cDNA fragment that was isolated from pcdNA3-myc-PML (56) into pEGFP-C1.

Protein Expression and Purification—Escherichia coli BL21(DE3)(pET-Rta, pT-E1E2S2) was treated with isopropyl 1-thio-β-D-galactopyranoside to induce the expression of His-tagged polySUMO-2-Rta according to a method described earlier (53). His-Rta and His-UbcH5a were purified from the E. coli BL21(DE3)(pET-Rta) and E. coli BL21(DE3)(pET-Ubc5a) lysates, respectively, using Ni²⁺-NTA-Sepharose beads using the method described elsewhere (44).

SUMO modification of Rta does not involve LF2-mediated repression of the functions of Rta (49). This study demonstrates that Rta is ubiquitinated via the interaction with RNF4. Moreover, RNF4 targets SUMO-2-conjugated Rta to enhance Rta ubiquitination, thus decreasing the stability of Rta and affecting EBV lytic progression.

EXPERIMENTAL PROCEDURES

Cell Lines and EBV Lytic Induction—P3HR1 cells were cultured in RPMI 1640 medium. 293T cells were cultured in Dulbecco’s modified Eagle’s medium. The media were supplemented with 10% fetal calf serum. To induce the EBV lytic cycle, P3HR1 cells were treated with 3 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA) and 3 mM sodium butyrate for 24–48 h (51, 52).

Plasmids—Plasmid pGEX-4T1, which expresses GST, was purchased from Amersham Biosciences. Plasmids pHis-UbcH5a, pGEX-RNF4, and pEGFP-RNF4 encode His-UbcH5a, RNF4, and GFP-RNF4, respectively.4 Plasmids pBMLF1, pCMV-R, pFLAG-Rta, and pET-Rta were described elsewhere (41, 44, 46). Plasmid pFLAG-Ub, which expressed FLAG-tagged ubiquitin, was constructed by inserting a PCR-amplified DNA fragment that encoded ubiquitin into the EcoRI-HindIII sites in pCMV-Tag2B (Stratagene). Plasmid pT-E1E2S2 contains SUMO E1-, SUMO E2-, and SUMO-2-coding sequences cloned downstream of a T7 promoter (53). Plasmids that express FLAG-RNF4, an RNF4 RING finger mutant that contains two point mutations, C136S and C139S (FLAG-RNF4-C136S/139S), were provided by Ronald T. Hay (15, 54).

RNF4 and Rta Ubiquitination

4 Y. C. Yang, Y. Yoshikai, S. W. Hsu, H. Saitoh, and L. K. Chang, manuscript in preparation.
RNF4 and Rta Ubiquitination

Alexa Fluor 594-conjugated goat anti-rabbit IgG polyclonal antibody (Invitrogen), or Cy5-conjugated goat anti-mouse IgG polyclonal antibody (Invitrogen). Nuclei were visualized by staining using 5 µg/ml 4′,6-diamidino-2-phenylindole (DAPI). Finally, cells were examined under a Zeiss confocal laser-scanning microscope (Model LSM780) (Oberkochen, Germany).

In Vitro Ubiquitination Assay—The reaction mixture (20 µl) contained 4.8 µg of bovine ubiquitin (Sigma), 56 ng of E1 protein (Boston Biochem), 160 ng of purified His-UbcH5a protein, GST-RNF4-glutathione beads, and His-Rta or poly-SUMO-2-conjugated His-Rta in a reaction buffer that contained 5 mM MgCl₂, 2 mM ATP, and 0.2% Triton X-100 in PBS. Reaction mixtures were incubated for 1 h at 32 °C with shaking. Proteins were separated by SDS-polyacrylamide gel electrophoresis and detected by immunoblotting. Similar reaction mixtures contained FLAG-ubiquitin (Sigma), E1, UbcH5a, GST-RNF4, and His-Rta, or SUMO-2-Rta was added in 100 µl of SUMO-protective buffer containing 1% SDS and then boiled at 95 °C for 10 min. The mixtures were then diluted with 900 µl PBS containing 0.5% Nonidet P-40. Ub-Rta was immunoprecipitated using anti-FLAG antibody and separated by SDS-polyacrylamide gel electrophoresis and detected by immunoblotting using anti-Rta antibody.

Transient Transfection and Luciferase Assay—P3HR1 cells (5 × 10⁶) were transfected with 5 µg of plasmids under the conditions of 240 V, 975 microfarads by electroporation using a BTX ECM630 electroporator (BTX Instrument). Plasmid DNA was transfected into 293T cells using Turbofect in vitro transfection reagent (Fermentas). To examine promoter activities, cells were harvested and washed with PBS, then lysed in 30 µl lysis buffer containing 25 mM Tris phosphate (pH 7.8), 2 mM dithiothreitol, 2 mM 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol, and 1% Triton X-100. Luciferase activity was measured according to a method described earlier using a luminometer (Orion II; Berthod, Bad Wildbad, Germany) (58). Each transfection experiment was performed at least three times, and each sample in the experiment was prepared in duplicate.

Quantitative Reverse Transcription-PCR—Total RNA was extracted from P3HR1 cells at 0–36 h after treatment with 1.25 µM MG132. cDNA was amplified using random hexamers and Moloney murine leukemia virus reverse transcriptase (Promega). Real-time quantitative PCR was performed according to the method as described (41). Primers used for amplification of BRFL1 and actin were described earlier (59).

Analysis of Protein Stability—293T cells were cotransfected with pCMV-R and RNF4 shRNA or control shRNA and then cultured for 40 h; thereafter, cells were treated with 100 µg/ml cycloheximide (Sigma) to inhibit protein synthesis. Cells were harvested at different time points after the treatment. The amounts of RNF4, Rta, and α-tubulin were determined by immunoblot analysis.

Knockdown of RNF4 Expression Using shRNA—RNF4 shRNAs and plasmids including pVSV-G, pCMVDR8.91, and pLKO-shRNA were purchased from the National RNAi Core Facility, Genomic Research Center, Academia Sinica, Taipei, Taiwan. Two plasmids (300 ng) that express RNF4 shRNAs (target sequences 5′-CGGGCTTTCTGACTGCTCCATA and 5′-CATCTGATGGACGGATCTC) were transfected into 293T cells using Turbofect in vitro transfection reagent (Fermentas). Inhibition of RNF4 expression was examined by immunoblotting using anti-RNF4 antibody at 48 h after transfection. For lentiviral infection, RNF4 shRNAs were cotransfected into HEK-293T cells with pVSV-G and helper plasmids pCMVDR8.91 using Turbofect reagent. Plasmid pLKO-shRNA was used as a negative control. The culture supernatants were harvested and used to transduce P3HR1 cells to knockdown endogenous RNF4 expression according to the method provided by the National RNAi Core Facility. Stable cell lines were selected using 0.5 µg/ml puromycin.

Determination of DNA Replication and the Copy Number of EBV Genome—P3HR1 cells that expressed RNF4-shRNA were treated with TPA and sodium butyrate to induce the lytic cycle.
Viral replication was assayed by real-time PCR using primers for the oriLyt DNA region then normalized to cellular actin DNA as described earlier (60). To determine the copy number of EBV, virus particles released into the culture medium were harvested by ultracentrifugation at 25,000 g for 2 h using P3HR1 cells that had been treated with TPA and sodium butyrate for 5 days. qPCR was conducted according to the method as described (61).

RESULTS

Stabilization of Sumoylated Rta (SUMO-Rta) by MG132—293T cells were cotransfected with plasmids that express Rta and SUMO-1 or Rta and SUMO-2 to investigate how MG132 treatment affected Rta sumoylation. Immunoblot analysis using anti-Rta antibody revealed the presence of Rta in the lysates from the cells transfected with pCMV-R (Fig. 1A, Input, lanes 3–5 and 8–10). Meanwhile, a band that was larger than Rta, which is likely SUMO-Rta, was detected in the lysates from the cells that were cotransfected with pCMV-R or pCMV-R and pCR-SUMO-1 or pCR-SUMO-2 and treated with MG132 (Fig. 1A, Input, lanes 8–10). A control experiment showed that anti-FLAG antibody did not immunoprecipitate Rta that was conjugated by FLAG-SUMO if the cells were not transfected with pCR-SUMO-1 or pCR-SUMO-2 (Fig. 1A, IP, lanes 3 and 8). This study also cotransfected cells with pCMV-R and pCR-SUMO-1 or pCR-SUMO-2. Proteins were then immunoprecipitated using anti-FLAG antibody after denaturing proteins in the lysates at 95 °C. Subsequent immunoblot analysis using anti-Rta antibody revealed a SUMO-Rta band of 120 kDa (Fig. 1A, IP, lanes 4 and 5). Meanwhile, treating the cells with MG132 after transfection caused the accumulation of 120-kDa SUMO-Rta and the appearance of a 140-kDa SUMO-Rta band (Fig. 1A, IP, lanes 9 and 10); the amounts of these two proteins were considerably larger than the 120-kDa SUMO-Rta detected in the cells untreated with MG132 (Fig. 1A, IP, lanes 4 and 5). Notably, the 140-kDa SUMO-Rta co-migrated with a protein that was detected nonspecifically under the experimental conditions (Fig. 1A, IP, lanes 1–8). In fact, bands of 90 and 135 kDa, which are not Rta and sumoylated Rta, respectively, are often nonspecifically detected when an experiment involves immunoprecipitation using anti-FLAG antibody and immunoblot analysis using anti-Rta antibody (46, 62, 63). This study also cotransfected 293T cells with pFLAG-Rta and pHA-SUMO-1 or pFLAG-Rta and pHA-SUMO-2. Experimental results indicated that FLAG-Rta was expressed after cotransfection (Fig. 1B, Input). Furthermore, HA-SUMO-Rta in the lysates was immunoprecipitated using anti-FLAG antibody after the proteins in the lysate were denatured by heat and then immunoblotted using anti-HA antibody to reveal FLAG-Rta that was conjugated by HA-SUMO-1 or HA-SUMO-2. Those results further demonstrated that SUMO-Rta was undetected in the lysates from the cells cotransfected with pFLAG-Rta and pHA-SUMO-1 or pFLAG-Rta and pHA-SUMO-2 (Fig. 1B, IP, lanes 4 and 5). However, SUMO-Rta was detected if the cells were treated with MG132 after cotransfection (Fig. 1B, IP, lanes 9 and 10), suggesting that MG132 treatment stabilizes SUMO-Rta.

MG132 Treatment and EA-D Expression—This study investigated whether the stabilization of SUMO-Rta by MG132...
caused the expression of an EBV early protein, EA-D. Accordingly, P3HR1 cells were treated with MG132 for 36 h without lytic induction. Immunoblot analysis revealed that the amounts of Rta and EA-D increased substantially at 36 h after the treatment (Fig. 2A), indicating that the treatment with MG132 causes the expression of EA-D (Fig. 2A). Indirect immunofluorescence analysis also revealed the presence of Rta as speckles in the cells after 6 h of MG132 treatment (Fig. 2B). The number and intensity of Rta dots increased over the 36-h incubation period (Fig. 2B), verifying that MG132 stabilizes Rta. Meanwhile, qRT-PCR revealed that MG132 treatment increased only a slight amount of the BRLF1-BZLF1 transcript (Fig. 2C), possibly due to leaky transcription of the genes in P3HR1 cells (64). Additionally, the amount of mRNA detected after MG132 treatment was about 1% or less than that after lytic induction (Fig. 2C), implying that the enhanced EA-D and Rta expression after MG132 treatment is probably not due to transcriptional activation.

**Ubiquitination of Rta in Vivo**—MG132 is a proteasome inhibitor that prevents the degradation of proteins that are conjugated to ubiquitin. The fact that MG132 stabilizes SUMO-conjugated Rta implies that Rta is conjugated to ubiquitin before its degradation. This study attempted to demonstrate that Rta is ubiquitinated by cotransfecting 293T cells with...
pCMV-R and pFLAG-Ub. At 24 h after transfection, ubiquitinated proteins in the lysate were immunoprecipitated using anti-FLAG antibody. Ubiquitinated Rta (Ub-Rta) was subsequently detected by immunoblotting using anti-Rta antibody. The results indicated that cotransfecting the cells with both plasmids was necessary for detecting Ub-Rta (Fig. 3A, IP, lanes 2 and 4); transfecting the cells with pCMV-R alone was insufficient for such detection (Fig. 3A, IP, lanes 1 and 3). Additionally, the amount of Ub-Rta increased if the cells were treated with MG132 after transfection (Fig. 3A, IP, lane 4). We also found that after the cells were cotransfected with pCMV-R and pFLAG-Ub, Ub-Rta was immunoprecipitated by anti-Rta antibody and detected by immunoblotting using anti-FLAG antibody (Fig. 3A, IP, lane 6); treating the cells with MG132 further increased the amount of Ub-Rta (Fig. 3A, IP, lane 8). Furthermore, this study examined whether Rta was ubiquitinated in P3HR1 cells. If the cells were untreated with TPA and sodium butyrate, a trace amount of Ub-Rta was detected (Fig. 3B, IP, lane 2). Also, treating the cells with MG132 increased the amount of Ub-Rta (Fig. 3B, IP, lane 4). Meanwhile, after lytic induction for 24 h, the presence of Ub-Rta displayed a weak signal (Fig. 3B, IP, lane 6); treating the cells with MG132 after lytic induction resulted in the detection of an abundant amount of Ub-Rta (Fig. 3B, IP, lane 8). A control experiment involving immunoprecipitation in which an anti-IgG antibody was used did not allow for the detection of Ub-Rta (Fig. 3B, IP, lanes 1, 3, 5, and 7), demonstrating that Rta is conjugated to ubiquitin. Furthermore, this study used the same lysate to demonstrate that Rta was conjugated by SUMO-2/3. Accordingly, immunoblot analysis using anti-SUMO-2/3 antibody revealed that SUMO-2/3-Rta was undetected if the cells were untreated with TPA, sodium butyrate, and MG132 (Fig. 3B, IP, lane 2); treating the cells with MG132 or TPA and sodium butyrate resulted in the detection of a weak SUMO-2/3-Rta band (Fig. 3B, IP, lanes 4 and 6). Furthermore, treating the cells with MG132 after lytic induction substantially increased the amount of SUMO-2/3-Rta in the cells (Fig. 3B, IP, lane 8). A negative control showed that SUMO-Rta was undetected if immunoprecipitation involved anti-IgG antibody (Fig. 3B, IP, lanes 1, 3, 5, and 7). These results indicated that Rta was conjugated by SUMO-2/3 and the treatment with MG132 causes the accumulation of SUMO-2/3-Rta.

Interaction of RNF4 with Rta—Because RNF4 is known to promote ubiquitination of SUMO-2-conjugated proteins (15, 16, 27), this study investigated whether Rta interacts with RNF4 in a GST pulldown study. Glutathione-Sepharose beads were added to the lysate prepared from E. coli transformed with plasmids that express GST and GST-RNF4 (Fig. 4A, lanes 4 and 5). After washing, the beads were added to a lysate from E. coli BL21(DE3)(pET-Rta), which expresses His-Rta. Proteins that were bound to the beads were eluted and analyzed by immunoblotting using anti-Rta antibody. The result revealed that Rta in
the lysate (Fig. 4A, lane 1) was retained by GST-RNF4–glutathione-Sepharose beads (Fig. 4A, lane 3) but not by GST–glutathione-Sepharose beads (Fig. 4A, lane 2), indicating that RNF4 binds to Rta directly. Thereafter, communoprecipitation assay was performed using P3HR1 cells that had been treated with TPA and sodium butyrate for 24 h. Immunoblot analysis revealed that Rta in the lysate (Fig. 4B, lane 1) was immunoprecipitated by anti-Rta antibody (Fig. 4B, lane 4) and communoprecipitated with RNF4 by anti-RNF4 antibody (Fig. 4B, lane 3). However, Rta was not immunoprecipitated by anti-IgG antibody (Fig. 4B, lane 2). A parallel experiment revealed that RNF4 was present in the P3HR1 cell lysate (Fig. 4B, lane 5), immunoprecipitated by anti-RNF4 antibody (Fig. 4B, lane 8), and communoprecipitated with Rta by anti-Rta antibody (Fig. 4B, lane 7). However, anti-IgG antibody did not immunoprecipitate RNF4 (Fig. 4B, lane 6). Indirect immunofluorescence also revealed that GFP–RNF4 colocalized with Rta and displayed a punctate distribution in the nucleus in P3HR1 cells after the cells were transfected with pEGFP-RNF4, treatment with TPA, sodium butyrate, and MG132 (Fig. 4C, h). As is generally known, lytic induction using TPA and sodium butyrate of EBV in B lymphocyte cells is usually inefficient and does not cause the expression of lytic proteins in all the cells (65–68), explaining why only a subset of P3HR1 population was lytically activated and expressed Rta (Fig. 4C, g and h). The study also found that GFP was diffused throughout the cells when the cells were transfected with an empty vector (Fig. 4C, a–d).

Promotion of Rta Ubiquitination by RNF4 in vitro—An in vitro ubiquitination assay was performed using purified Rta, ubiquitin E2 enzyme UbcH5a, GST–RNF4, and ubiquitin-activating E1 enzyme. Ub-Rta in the reaction mixture was then detected by immunoblotting using anti-Rta antibody (Fig. 5A). The results showed that His-Rta purified from E. coli BL21(DE3)(pET-Rta) was not sumoylated (Fig. 5A, lane 1). However, His-Rta was sumoylated by SUMO-2 in E. coli BL21(DE3)(pT-E1E2S2) (53) (Fig. 5A, lane 2), although a large amount of Rta was unsumoylated. The assay revealed that neither a blank, which contained only ubiquitin, E1, E2, and ATP (Fig. 5A, lanes 3 and 4), nor adding His-Rta to the blank reaction mixture resulted in protein ubiquitination (Fig. 5A, lanes 5–7). However, adding an Rta mixture that contained SUMO-2-His-Rta to the reaction produced a band that was higher than that of SUMO-2-His-Rta when GST–RNF4 was present, suggesting that SUMO-2-His-Rta is ubiquitinated (Fig. 5A, lanes 9 and 10). The results also demonstrated that ubiquitination of SUMO-2-His-Rta required ATP (Fig. 5A, lanes 8 and 10). An in vitro ubiquitination assay was also conducted using FLAG–ubiquitin, purified His-Rta, an Rta mixture that contained SUMO-2-His-Rta, ubiquitin E2 enzyme UbcH5a, GST–RNF4, and ubiquitin-activating E1 enzyme to verify that RNF4 promotes the ubiquitination of SUMO-2-His-Rta. Ubiquitinated proteins were then immunoprecipitated using anti-FLAG antibody and detected by immunoblot analysis using anti-Rta antibody (Fig. 5B). The results revealed that SUMO-2-Rta was modified by FLAG-ubiquitin only when the reaction included GST–RNF4 (Fig. 5B, lane 6). The results also revealed that the ubiquitination of Rta depended on ATP (Fig. 5B, lanes 5 and 6). The above results indicate that SUMO-2-His-Rta is a substrate for RNF4 in vitro and RNF4 targets SUMO-2-His-Rta to promote Rta ubiquitination. The possibility that Rta influences the ubiquitination of RNF4 was excluded by a similar analysis. The results confirmed that GST–RNF4 autoubiquitinated in the reaction containing E1, E2, Ub, and ATP (Fig. 5C, lane 4), resulting in the detection of monoubiquitinated, diubiquitinated, and polyubiquitinated RNF4 by immunoblot analysis using anti-GST antibody. Asterisks indicate bands detected nonspecifically.

**FIGURE 5. Enhancement of Rta ubiquitination by RNF4 in vitro.** A. conjugation of ubiquitin to Rta was analyzed in vitro using purified Rta, an Rta mixture that contains SUMO-2-conjugated Rta, and GST–RNF4 in the presence of ubiquitin (Ub), ubiquitin E1-activating enzyme, and ubiquitin E2 enzyme (UbcH5a). Ubiquitinated proteins were examined by immunoblotting (IB) using anti-Rta antibody. B, similar in vitro Ub assay was conducted using FLAG-ubiquitin (FLAG–Ub), purified Rta, SUMO-2-conjugated Rta, GST–RNF4. Thereafter, Ub-Rta was immunoprecipitated (IP) using anti-FLAG antibody and then detected by immunoblotting using anti-Rta antibody. C, additionally, the ubiquitination of RNF4 was examined in vitro with purified GST–RNF4, Rta, or SUMO-2-conjugated Rta in the reaction mixture containing ubiquitin (Ub), ubiquitin E1-activating enzyme, UbcH5a, or ATP. Ubiquitinated proteins including monoubiquitinated, diubiquitinated, and polyubiquitinated GST–RNF4 were detected by immunoblot analysis using anti-GST antibody. Asterisks indicate bands detected nonspecifically.
RNF4 and Rta Ubiquitination

FIGURE 6. RNF4 and the ubiquitination of Rta. A, 293T cells were cotransfected with pCMV-R, pEGFP-RNF4, and pFLAG-Ub (lanes 1–5). At 24 h after transfection cells were treated with 5 μM MG132 for another 12 h. Proteins in the lysate were immunoprecipitated (IP) using anti-FLAG antibody. Proteins bound to FLAG-M2 beads were analyzed by immunoblot analysis (IB) using anti-Rta and anti-GFP antibodies. Similarly, 293T cells were cotransfected with plasmids that express FLAG-Rta, GFP-RNF4, and FLAG-Ub (lanes 6–10). At 24 h after transfection, cells were treated with 5 μM MG132 for another 12 h. Proteins in the lysate were immunoprecipitated using anti-FLAG antibody. Proteins bound to FLAG-M2 beads were analyzed by immunoblot analysis using anti-HA, anti-Rta, and anti-GFP antibodies. B, shown is the effect of knockdown of RNF4 on the ubiquitination of Rta. 293T cells were cotransfected with plasmids that express FLAG-Ub, Rta, and RNF4 shRNA or control shRNA (Ct-shRNA) and then treated with 5 μM MG132 for 12 h. Ubiquitinated Rta was immunoprecipitated using anti-FLAG antibody and detected by immunoblotting using anti-Rta antibody. C, 293T cells were cotransfected with pHA-Ub, pCMV-R, and pFLAG-RNF4 or pFLAG-RNF4-CS1. At 24 h after transfection, cells were treated with 5 μM MG132 for another 12 h. Proteins in the cell lysate were immunoprecipitated using anti-HA antibody. Immunoprecipitated proteins were detected by immunoblotting with anti-Rta antibody. D, a similar experiment as described in C was conducted except that pFLAG-RNF4-CS1 was replaced with pFLAG-RNF4-mSIM. E, interaction of Rta with RNF4 mutants is shown. 293T cells were cotransfected with pEGFP-Rta and plasmids that express FLAG-RNF4, FLAG-RNF4-CS1, or FLAG-RNF4-mSIM. A coimmunoprecipitation assay was performed using anti-FLAG antibody, and immunoprecipitated proteins were detected by immunoblotting with anti-GFP antibody (lanes 6–10). Asterisks indicate bands detected nonspecifically. Ub-Rta, ubiquitinated Rta.

Enhancement of Rta Ubiquitination by RNF4 in Vitro—After demonstrating that RNF4 promotes ubiquitination of Rta in vitro, this study verified the function of RNF4 as an STUbL of Rta in vivo. Accordingly, 293T cells were cotransfected with pCMV-R, pEGFP-RNF4, and pFLAG-Ub, and proteins in the lysate were then immunoprecipitated by anti-FLAG antibody. Immunoblotting using anti-Rta antibody revealed that ubiquitinated Rta was undetected after cells were transfected with pCMV-R or pFLAG-Ub (Fig. 6A, IP, lanes 1 and 2). However, a little Ub-Rta was detected after cells were cotransfected with plasmids that express Rta and FLAG-Ub (Fig. 6A, IP, lane 3). Transfecting the plasmids expressing Rta, FLAG-Ub, and GFP-RNF4 substantially increased the amount of Ub-Rta that was detected by immunoblotting (Fig. 6A, IP, lane 4). Meanwhile, GFP-RNF4 appeared to influence Rta ubiquitination in a dose-dependent manner (Fig. 6A, IP, lanes 4 and 5). 293T cells were also cotransfected with pFLAG-Rta, pEGFP-RNF4, and pHA-Ub, and proteins in the cell lysate were immunoprecipitated using anti-FLAG antibody and examined by immunoblotting using anti-HA antibody. The results revealed that Ub-Rta was detected when cells were cotransfected with pFLAG-Rta, pHA-Ub, and pEGFP-RNF4 in a dose-dependent manner (Fig. 6A, IP, lanes 9 and 10) but not in the cells that were not transfected by pEGFP-RNF4 (Fig. 6A, IP, lanes 6–8). A similar study also attempted to determine how RNF4 shRNA affected Rta ubiquitination. Our control experiment first demonstrated that transfecting RNF4 shRNA caused the accumulation of GFP-PML (data not shown), which is a known substrate of RNF4 (15, 27), to demonstrate that the transfected shRNA is functional. Subsequently, 293T cells were transfected with RNF4 shRNA to determine whether RNF4 reduces Rta ubiquitination. In a control experiment, immunoblotting did not detect Ub-Rta in cells that were transfected with only pCMV-R or pFLAG-Ub (Fig. 6B, IP, lanes 1 and 2). Ub-Rta was detected in cells that were cotransfected with pCMV-R, pFLAG-Ub, and control shRNA (Fig. 6B, IP, lane 3). However, introducing RNF4 shRNA reduced the amount of Ub-Rta (Fig. 6B, IP, lane 4). A similar transfection experiment was performed using the RING mutant of RNF4 (FLAG-RNF4-CS1), which showed that although FLAG-RNF4 promoted the ubiquitination of Rta (Fig. 6C, IP, lanes 3 and 4), FLAG-RNF4-CS1 did not influence the ubiquitination of Rta (Fig. 6C, IP, lane 5). Furthermore, FLAG-RNF4 with mutation at its SIM domains (FLAG-RNF4-mSIM) also failed to promote the ubiquitination of Rta (Fig. 6D, IP, lane 5), suggesting that RNF4-mediated Rta ubiquitination depends on the SIM motifs of RNF4. This study also examined the interaction of Rta with RNF4 mutants, including RNF4-CS1 and RNF4-mSIM. Accordingly, 293T cells were cotransfected with pEGFP-Rta and pFLAG-RNF4, pFLAG-RNF4-CS1, or pFLAG-RNF4-mSIM. Proteins in the
lysate were immunoprecipitated by anti-FLAG antibody and detected by immunoblotting using anti-GFP antibody. Analysis results indicated that Rta interacted with FLAG-RNF4 and FLAG-RNF4-CS1 (Fig. 6E, lanes 8 and 9). Mutation of SIM in RNF4 revealed a weak interaction with Rta (Fig. 6E, lane 10) even though the expression level of FLAG-RNF4-mSIM was higher (Fig. 6E, lane 5) than that of FLAG-RNF4-CS1 and FLAG-RNF4 (Fig. 6E, lanes 3 and 4).

SUMO-dependent Ubiquitination of Rta by RNF4—An earlier study indicated that mutation of Rta at lysine residues 426, 446, 517, and 530 eliminates SUMO-3 conjugation to Rta (49). Our earlier investigation also demonstrated that Rta is conjugated to SUMO-1 via lysine residues 19, 213, and 517 (44). Therefore, in this study, pHA-3K-R and pHA-4K-R, which encodes mutant Rta with mutations of the three and four lysine residues with which SUMO-1 and SUMO-2/3 conjugate, respectively, are generated to examine how these mutations affect Rta ubiquitination. Here, the transfection study revealed that although overexpressing FLAG-Ub and GFP-RNF4 caused the ubiquitination of Rta in 293T cells (Fig. 7A, IP, lane 4), cotransferring plasmids that express HA-Rta, HA-3K-R, or HA-4K-R, a coimmunoprecipitation assay was performed using anti-FLAG antibody, and immunoprecipitated proteins were detected by immunoblotting using anti-HA antibody. C, P3HR1 cells were transfected with plasmids pEGFP-RNF4 (a–r), and then cells were treated with 5 μM MG132 or DMSO for 12 h after lytic induction by TPA and sodium butyrate. Cells were incubated with anti-Rta monoclonal antibody and anti-SUMO-2 polyclonal antibody. DAPI staining revealed the nucleus. Thereafter, cells were observed under a confocal laser-scanning microscope. d, h, m, and r are merged images.

Reduced Rnf4 and Rta Ubiquitination

The results revealed that Rta colocalized with SUMO-2 in the nucleus as dots when cells were treated with MG132 (Fig. 7C, h). Rta was also colocalized with SUMO-2 and RNF4 in the nucleus after MG132 treatment (Fig. 7C, r), suggesting that RNF4 targets SUMO-2-conjugated Rta to enhance its ubiquitination after lytic induction.
Effect of RNF4 on the Stability and the Transactivation Activity of Rta—Whether the expression of RNF4 shRNA influences the stability of Rta was investigated by cotransfecting 293T cells with plasmids pCMV-Rta and RNF4 shRNA or control shRNA. At 40 h after transfection, cells were treated with cycloheximide (CHX) for 150 min to inhibit protein synthesis. The result showed that the amount of Rta decreased ~50% at 150 min if cells were transfected with control shRNA (Fig. 8, A and B). Yet the level of Rta was reduced 12% at 150 min in the presence of RNF4 shRNA (Fig. 8, A and B), demonstrating that RNF4 reduces the stability of Rta. This study also examined whether RNF4 affects the transactivation ability of Rta via ubiquitination by undertaking a transient transfection study in which 293T cells were cotransfected with pBMLF1, pCMV-R, and pEGFP-RNF4. According to those results, overexpressing Rta increased the promoter activity by 9.7-fold (Fig. 8C). RNF4 inhibited the transactivation activity of Rta in a dose-dependent manner from 7.3- to 5.9-fold after transfection with 0.1–0.3 μg of pEGFP-RNF4 (Fig. 8C). Notably, the promoter activity activated by Rta was not significantly reduced if cells were cotransfected with the same amounts of an RNF4 mutant, RNF4-CS1 (Fig. 8C), indicating that RNF4 decreases the ability of Rta to transactivate an EBV lytic promoter. Our results further demonstrated using the RNF4-mSIM to compete the function of RNF4 is ineffective (data not shown), likely due to its weak interaction with Rta (Fig. 6F).

Role of RNF4 in EBV Lytic Development—The expression of RNF4 in P3HR1 cells was attenuated using lentiviral-based shRNA (Fig. 9A). Rta and EA-D were expressed when cells were infected with lentiviral control shRNA after lytic induction (Fig. 9A, lanes 1 and 2). Additionally, knockdown of RNF4 expression by RNF4 shRNA increased the expression of Rta and EA-D (Fig. 9A, lanes 2 and 4). Moreover, lytic DNA replication was examined by performing qPCR. The result revealed that the inhibition of RNF4 expression using shRNA increased the level of viral DNA replication by 5.5-fold after the cells were treated with TPA and sodium butyrate (Fig. 9B). Finally, virion production was examined using qPCR. According to those results, knockdown of RNF4 expression also increased the production of virions by 5-fold after lytic induction (Fig. 9C), demonstrating that RNF4 inhibits EBV lytic progression.

DISCUSSION

Rta is a transcription factor that activates viral early genes, subsequently affecting lytic progression (48, 49, 59, 69–73). Hence, the stability of Rta is essential to its ability to influence the lytic cycle. Our results demonstrate for the first time that Rta is a substrate of RNF4 that targets SUMO-2-conjugated Rta and enhances the ubiquitination of Rta, ultimately inhibiting EBV lytic progression.

Our earlier study established that RanBPM promotes Rta sumoylation and enhances its transactivation activity (46). According to those results, treating cells with 0.5 μM MG132 stabilizes sumoylated Rta in P3HR1 cells (46). Because MG132 inhibits the proteolytic activity of 26 S proteasome complex, preventing the degradation of ubiquitinated proteins (74), the fact that MG132 stabilizes sumoylated Rta (Fig. 1) implies that Rta is conjugated by ubiquitin via polySUMO-2 chains. Based on the result herein, MG132 indeed stabilizes SUMO-1 and SUMO-2-conjugated Rta (Fig. 1, A and B, IP, lanes 9 and 10). When cells were untreated with MG132, the sumoylated Rta was relatively unstable even in the presence of N-ethylmaleimide, which is a SUMO hydrolase inhibitor (Fig. 1, A and B, IP, lanes 4 and 5). Moreover, because SUMO-1 acts as a chain terminator by linking to the ends of polySUMO-2/3 chains (9), distinguishing the SUMO-1 on the polySUMO chain from multiple monosumoylated Rta in vivo may be difficult. Therefore,
MG132 may protect Rta that is conjugated by both SUMO-1 or SUMO-2/3 (Fig. 1). This study also finds that MG132 treatment does not substantially activate the transcription of BRLF1-BZLF1 genes in P3HR1 cells (Fig. 2C) but accumulates endogenously expressed Rta, which are verifiable by immunoblot and immunofluorescence analyses (Figs. 2, A and B), suggesting that MG132 affects the stability rather than the transcriptional functions of Rta.

This study demonstrates that Rta is a substrate of RNF4, which is an STUbL that contains SIM and RING domains (15, 54), causing the ubiquitination of SUMO-2-conjugated PML (15). According to our results, RNF4 enhances the ubiquitination of SUMO-2-conjugated Rta in an in vitro ubiquitination assay (Fig. 5B). Earlier studies demonstrated that RNF4 interacts with either the polySUMO-2 chain on PML or Sp1 directly to promote ubiquitination (15, 27, 28), although whether RNF4 preferentially binds to SUMO-2-conjugated substrates remains unknown (22, 75, 76). GST pulldown assays herein reveal that Rta interacts with RNF4 (Fig. 4A), suggesting that the direct interaction between the two proteins or the interaction with the SUMO-2 chain on Rta is important to Rta ubiquitination. This interaction is also verified by immunofluorescence analysis (Fig. 4C). According to earlier studies, GFP-RNF4 is distributed diffusely in the nucleus (36) but has a punctate distribution and colocalizes with PML nuclear bodies after treatment with arsenic (77). The present study reveals that GFP-RNF4 is diffused in cells that are untreated with MG132. However, MG132 treatment causes the punctate distribution (Fig. 4C), possibly because MG132 treatment changes the cellular distributions of the proteasome and the proteins that are associated with the PML nuclear bodies (78).

This study demonstrates that RNF4 enhances Rta ubiquitination (Figs. 5 and 6). The first piece of evidence is that an abundant amount of ubiquitinated proteins is formed in vitro in the reaction involving SUMO-2-Rta, GST-RNF4, ubiquitin, E1, E2, and ATP (Fig. 5A, lane 10). Immunoprecipitation of these ubiquitinated proteins reveals the formation of Ub-Rta, as detected by immunoblotting using anti-Rta antibody (Fig. 5B), suggesting that SUMO-2-conjugated Rta is a preferred substrate for RNF4 in vitro (Fig. 5B, lane 6). However, demonstrating the occurrence of this phenomenon in vivo is relatively difficult. Moreover, although apparently not influencing the ubiquitination of RNF4 (Fig. 5C, lanes 5–8), Rta likely does not function as an E3 ligase despite the fact that the homologs of Rta in KSHV and murine herpesvirus 68 have E3 ligase activity in vitro (79–82). Additionally, introducing RNF4 shRNA to the cell significantly reduced the level of ubiquitinated Rta (Fig. 6B), indicating that RNF4 is critical to Rta ubiquitination. The fact that mutation of SIMs or a RING domain in RNF4 abolishes the ubiquitination of Rta (Fig. 6, C and D) also supports the role of RNF4 as an STUbL to promote Rta ubiquitination. Moreover, mutations in the SIM domain in RNF4 decrease the interaction of the protein with Rta (Fig. 6E) and abolish Rta ubiquitination (Fig. 6D), demonstrating the importance of such an interaction.

The phenomenon in which ubiquitination of the 4K-R mutant of Rta significantly reduces in vivo (Fig. 7A) also suggests that SUMO-2 modification at these four lysine residues is important to Rta ubiquitination; RNF4 also functions as an STUbL of Rta that promotes ubiquitination via polySUMO-2 chains. Furthermore, a previous study indicated that Rta is modified by SUMO-3 (49). By using the SUMO-3-defective Rta mutant (HA-4K-R), this study demonstrates that HA-4K-R is ubiquitinated at a level significantly lower than that of HA-Rta (Fig. 7A). HA-3K-R (44) has a similar ubiquitination pattern to that of wild-type Rta (Fig. 7A), verifying that Rta is not ubiquitinated by RNF4 via sumoylation by SUMO-1. This finding is consistent with the fact that SUMO-2-Rta is a preferred substrate for RNF4 in vitro (Fig. 5B). This study also demonstrates that MG132 treatment of P3HR1 cells leads to the accumulation of SUMO-2-Rta and ubiquitinated Rta simultaneously after lytic induction (Fig. 3B). This finding verifies that Rta is ubiquitinated via SUMO-2 chains. Confocal microscopy analysis also reveals that Rta, SUMO-2, and RNF4 colocalize in the nucleus if cells are treated with MG132 (Fig. 7C). This finding demonstrates that RNF4 indeed binds to SUMO-2-Rta in vivo. In sum, results of this demonstrate that RNF4 is an STUbL of Rta.

This study finds that RNF4 is a cellular STUbL that targets Rta for ubiquitination (Figs. 5 and 6) to decrease the transactivation ability and stability of Rta (Fig. 8). We also demonstrate that inhibiting RNF4 expression enhances the expression of EA-D (Fig. 9A) and promotes lytic DNA replication and virions production (Fig. 9, B and C). Although the influence of Rta ubiquitination on the EBV lytic cycle need to be verified further,
this study provides insight into the mechanism that modulates the amount of Rta by the cell, which may be important to EBV lytic development.

Acknowledgments—We thank Shih-Tung Liu for criticism and suggestions. We also thank Ronald T. Hay for providing FLAG-RNF4-CS1 and FLAG-RNF4-mtSIM plasmids and Shih-Chung Chang for providing pHA-Ub, pHA-SUMO-1, and pHA-SUMO-2.

REFERENCES

1. Pickart, C. M., and Fushman, D. (2004) Polyubiquitin chains. Polymeric protein signals. Curr. Opin. Chem. Biol. 8, 610–616
2. Grabbe, C., Huisnajk, K., and Dikic, I. (2011) The spatial and temporal organization of ubiquitin networks. Nat. Rev. Mol. Cell Biol. 12, 295–307
3. Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda, D. K., and Varshavsky, A. (1989) A multiquitin chain is confined to specific sites in a targeted short-lived protein. Science 243, 1576–1583
4. Thrower, J. S., Hoffman, L., Rechsteiner, M., and Pickart, C. M. (2000) Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94–102
5. Komander, D. (2009) The emerging complexity of protein ubiquitination. Biochem. Soc. Trans. 37, 937–953
6. Schwartz, D. C., and Hochstrasser, M. (2003) A superfamily of protein tags. Ubiquitin, SUMO, and related modifiers. Trends Biochem. Sci. 28, 321–328
7. Johnson, E. S. (2004) Protein modification by SUMO. Annu. Rev. Biochem. 73, 355–382
8. Tatham, M. H., Iaffray, E., Vaughan, O. A., Desterro, J. M., Botting, C. H., Naismith, J. H., and Hay, R. T. (2001) Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276, 35368–35374
9. Matic, I., van Hagen, M., Schimmel, J., Macek, B., Ogg, S. C., Tatham, M. H., Hay, R. T., Lamond, A. I., Mann, M., and Vertegaal, A. C. (2008) In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol. Cell Proteomics 7, 132–144
10. Wilkinson, K. A., and Henley, J. M. (2010) Mechanisms, regulation and consequences of protein SUMOylation. Biochem. J. 428, 133–145
11. Praefcke, G. J., Hofmann, K., and Dohmen, R. J. (2012) SUMO playing tag. FEBS Lett. 580, 56–62
12. Lallemand-Breitenbach, V., Jeanne, M., Benhenda, S., Nasr, R., Lei, M., Peres, L., Zhou, J., Zhu, J., Raught, B., and de Thé, H. (2008) Arsenic degrades PML or PML-RARα through a SUMO-targeted RNF4 ubiquitin ligase activity. FEBS Lett. 580, 56–62
13. Galanty, Y., Belotserkovskaya, R., Coates, J., and Jackson, S. P. (2012) SUMO-targeted ubiquitin E3 ligase RNF4 regulates the localization and function of Rta in EBV-infected cells. J. Virol. 86, 12890–12900
14. Kenney, S., Holley-Guthrie, E., Mar, E. C., and Smith, M. (1989) The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) responsive to the BZLF1 and BRLF1 transactivators. EMBO J. 8, 3243–3249
15. Chevallier-Greco, A., Manet, E., Chavrier, P., Mosnier, C., Daillie, J., and Sergeant, A. (1986) Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required for inner kinetochore assembly. J. Cell Biol. 103, 133–145
16. Sun, H., Leverson, J. D., Baker, R. K., Miraglia, L., Orth, A. P., Lyons, G. E., Schultz, P. G., and Wu, X. (2010) Identification of RING finger protein 4 (RNF4) as a modulator of DNA demethylation through a functional genomics screen. Proc. Natl. Acad. Sci. U.S.A. 107, 15087–15092
17. Yin, Y., Seifert, A., Chua, J. S., Maure, J. F., Golebiowski, F., and Hay, R. T. (2012) SUMO-targeted ubiquitin E3 ligase RNF4 is required for the response of human cells to DNA damage. Genes Dev. 26, 1196–1208
18. Galanty, Y., Belotserkovskaya, R., Coates, J., and Jackson, S. P. (2012) RNF4, a SUMO-targeted ubiquitin ligase, promotes DNA double-strand break repair. Genes Dev. 26, 1179–1195
19. Luo, K., Zhang, H., Wang, L., Yuan, J., and Lou, Z. (2012) Sumoylation of MDC1 is important for proper DNA damage response. EMBO J. 31, 3008–3019
20. Fryrear, K. A., Guo, X., Kerscher, O., and Semmes, O. J. (2012) The SUMO-targeted ubiquitin ligase RNF4 regulates the localization and function of the HTLV-1 oncoprotein Tax. Blood 119, 1173–1181
21. Chevallier-Greco, A., Manet, E., Chavrier, P., Mosnier, C., Daillie, J., and Sergeant, A. (1986) Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required for inner kinetochore assembly from an EBV early promoter. EMBO J. 5, 3243–3249
22. Kenney, S., Holley-Guthrie, E., Mar, E. C., and Smith, M. (1989) The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J. Virol. 63, 3878–3883
23. Holley-Guthrie, E. A., Quinivan, E. B., Mar, E. C., and Kenney, S. (1990) The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64, 3753–3759
24. Girot, J. F., Mikaelian, I., Buisson, M., Manet, E., Joab, I., Nicolas, J. C., and Sergeant, A. (1991) Transcriptional interference between the EBV tran-
scription factors EB1 and R, both DNA-binding and activation domains of EB1 are required. *Nucleic Acids Res.* **19**, 1251–1258

41. Chang, L. K., Chuang, J. Y., Nakao, M., and Liu, S. T. (2010) MCAF1 and synergistic activation of the transcription of Epstein-Barr virus lytic genes by Rta and Zta. *Nucleic Acids Res.* **38**, 4687–4700

42. Ye, J., Gradoville, L., Daigle, D., and Miller, G. (2007) *De novo* protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi’s sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists. *J. Virol.* **81**, 9279–9291

43. Ye, J., Gradoville, L., and Miller, G. (2010) Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus bZLF1 and brf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line. *J. Virol.* **84**, 12405–12418

44. Chang, L. K., Lee, Y. H., Cheng, T. S., Hong, Y. R., Lu, P. J., Wang, J. I., Wang, W. H., Kuo, C. W., Li, S. S., and Liu, S. T. (2004) Post-translational modification of Rta of Epstein-Barr virus by SUMO-1. *J. Biol. Chem.* **279**, 38803–38812

45. Liu, S. T., Wang, W. H., Hong, Y. R., Chuang, J. Y., Lu, P. J., and Chang, L. K. (2006) Sumoylation of Rta of Epstein-Barr virus is preferentially enhanced by PIASxβ. *Virus. Res.* **119**, 163–170

46. Chang, L. K., Liu, S. T., Kuo, C. W., Wang, W. H., Chuang, J. Y., Bianchi, E., Holthaus, A. M., Ewence, A. E., Li, N., Hirozane-Kishikawa, T., Hill, D. E., Vidal, M., Kieff, E., and Johannsen, E. (2007) Epstein-Barr virus and virus human protein interaction maps. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 7606–7611

47. Calderwood, M. A., Holthaus, A. M., and Johannsen, E. (2008) The Epstein-Barr virus LF2 protein inhibits viral replication. *J. Virol.* **82**, 8509–8519

48. Heilman, A. M., Calderwood, M. A., and Johannsen, E. (2010) Epstein-Barr virus LF2 protein regulates viral replication by altering Rta subcellular localization. *J. Virol.* **84**, 9920–9931

49. Zacny, V. L., Wilson, J., and Pagano, J. S. (1998) The Epstein-Barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle. *J. Virol.* **72**, 8043–8051

50. Davies, A. H., Grand, R. J., Evans, F. J., and Rickinson, A. B. (1991) Induction of the Epstein-Barr virus lytic cycle in latently infected cells by histone deacetylase inhibitors. *J. Virol.* **65**, 6838–6844

51. Liu, C., Sista, N. D., and Pagano, J. S. (1996) Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. *J. Virol.* **70**, 2545–2555

52. Liu, C., Li, S. S., and Liu, S. T. (2004) Post-translational modification of Rta of Epstein-Barr virus by SUMO-1. *J. Biol. Chem.* **279**, 405–409

53. Chiu, Y. F., Tung, C. P., Lee, Y. H., Wang, W. H., Lin, C. H., Hung, J. Y., Wang, C. Y., Kawaguchi, Y., and Liu, S. T. (2007) A comprehensive library of mutations of Epstein-Barr virus. *J. Gen. Virol.* **88**, 2463–2472

54. Sun, W., Tan, X., Shi, Y., Xu, G., Mao, R., Gu, X., Fan, Y., Yu, Y., Burlingame, S., Zhang, H., Rednam, S. P., Lu, X., Zhang, T., Fu, S., Cao, G., Qin, J., and Yang, J. (2010) USP11 negatively regulates TNFα-induced NF-κB activation by targeting on IkBa. *Cell. Signal.* **22**, 386–394

55. Oh, Y., Jeon, Y. J., Hong, G. S., Kim, I., Woo, H. N., and Jung, Y. K. (2012) Regulation in the targeting of TRAIL receptor 1 to cell surface via GOD2 for TRAIL sensitivity in tumor cells. *Cell Death Differ.* **19**, 1196–1207

56. Crawford, D. H., and Ando, I. (1986) EB virus induction is associated with B-cell maturation. *Immunology* **59**, 405–409

57. Countryman, J., Gradoville, L., Bhaduri-McIntosh, S., Ye, J., Heston, L., Himmelfarb, S., Shedd, D., and Miller, G. (2009) Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus. *J. Virol.* **83**, 10964–10970

58. Countryman, J. K., Gradoville, L., and Miller, G. (2008) Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. *J. Virol.* **82**, 4706–4719

59. Liu, C., Guda, Z., El-Guindy, A., and Miller, G. (2002) Protein kinase C-dependent activation of the Epstein-Barr virus lytic cycle. *J. Virol.* **76**, 5612–5626

60. Murata, T., Kondo, Y., Sugimoto, A., Kawashima, D., Saito, S., Isomura, H., Kanda, T., and Tsurumi, T. (2012) Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. *J. Virol.* **86**, 4752–4761

61. Feederle, R., Kost, M., Baumann, M., Janz, A., Drouet, E., Hammer-schmidt, W., and Delecluse, H. J. (2000) The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. *EMBO J.* **19**, 3080–3089

62. Liu, C., Sista, N. D., and Pagano, J. S. (1996) Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. *J. Virol.* **70**, 2545–2555

63. Gruffat, H., Manet, E., Rigolet, A., and Sergeant, A. (1990) The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. *Nucleic Acids Res.* **18**, 6528–6539

64. Chang, L. K., Chung, J. Y., Hong, Y. R., Ichimura, T., Nakao, M., and Liu, S. T. (2005) Activation of Sp1-mediated transcription by Rta of Epstein-Barr virus via an interaction with MCAF1. *Nucleic Acids Res.* **33**, 6528–6539

65. Adamson, A. L., Darr, D., Holley-Guthrie, E., Johnson, R. A., Mauser, A., Swanson, J., and Kenney, S. (2000) Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. *J. Virol.* **74**, 1224–1233

66. Lee, D. H., and Goldberg, A. L. (1998) Proteasome inhibitors. valuable new tools for cell biologists. *Trends Cell Biol.* **8**, 397–403

67. Wang, Z., and Prelich, G. (2009) Quality control of a transcriptional regulator by SUMO-targeted degradation. *Mol. Cell Biol.* **29**, 1694–1706

68. Parker, J. L., and Ulrich, H. D. (2012) A SUMO-interacting motif activates a SUMO-interacting motif-dependent transcriptional regulator. *J. Mol. Biol.* **422**, 405–409

69. Saito, S., Isomura, H., Kanda, T., and Tsurumi, T. (2012) Epigenetic histone modification of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. *Nucleic Acids Res.* **33**, 6528–6539

70. Mattsson, K., Pokrovskaja, K., Kiss, C., Klein, G., and Szekely, L. (2001) Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasome-dependent protein degradation. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 1012–1017

71. Yang, Z., Yan, Z., and Wood, C. (2008) Kaposi’s sarcoma-associated herpesvirus transactivator RTA promotes degradation of the repressors to
80. Yu, Y., Wang, S. E., and Hayward, G. S. (2005) The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteasome-mediated degradation. *Immunity* 22, 59–70

81. Gould, F., Harrison, S. M., Hewitt, E. W., and Whitehouse, A. (2009) Kaposi’s sarcoma-associated herpesvirus RTA promotes degradation of the Hey1 repressor protein through the ubiquitin proteasome pathway. *J. Virol.* 83, 6727–6738

82. Dong, X., He, Z., Durakoglugil, D., Arneson, L., Shen, Y., and Feng, P. (2012) Murine gammaherpesvirus 68 evades host cytokine production via replication transactivator-induced RelA degradation. *J. Virol.* 86, 1930–1941